论文部分内容阅读
目的:评价奈达铂联合紫杉醇(TN)同步放疗治疗Ⅲ、Ⅳa期颈段食管癌的局控率、生存率和毒副反应。方法:将50例患者随机分为TN组(n=25)和TP组(n=25)。TN组:紫杉醇135mg/m2 dl,奈达铂100mg/m2 dl;TP组:紫杉醇135mg/m2 dI,顺铂30mg/m2 dl-3。两方案均从放疗第一天开始化疗,21天为一周期,均化疗2周期。两组放疗方法相同,比较两组局控率、生存率和毒副反应。结果:CR率TN组为92%,TP组为84%,两组比较无统计学差异(P>0.05)。1年无复发生存率和1年无远处转移生存率TN组分别为92%,TP组为96%;PF组分别为88%和92%,两组比较差异有统计学意义(P<0.05)。骨髓毒性TN组高于TP组,差异有统计学意义(P<0.05),TP组恶性呕吐高于TN组,尤其ⅢⅣ级恶心、呕吐明显降低(P<0.05)。肝肾毒性,两组比较无统计学差异(P<0.05)。结论:奈达铂联合紫杉醇同步放疗治疗局部晚期颈段食管癌近期疗效确切,毒性反应较低,患者耐受好。
OBJECTIVE: To evaluate the rate of control, survival and toxicity of nedaplatin combined with paclitaxel (TN) concurrent radiotherapy for stage Ⅲ and Ⅳa cervical esophageal cancer. Methods: Fifty patients were randomly divided into TN group (n = 25) and TP group (n = 25). TN group: paclitaxel 135mg / m2 dl, nedaplatin 100mg / m2 dl; TP group: paclitaxel 135mg / m2 dI, cisplatin 30mg / m2 dl-3. Two programs are starting from the first day of radiotherapy chemotherapy, 21 days for a cycle, all 2 cycles of chemotherapy. Radiotherapy methods were the same in the two groups. The two groups were compared in terms of control rate, survival rate and toxicity. Results: The CR rate was 92% in the TN group and 84% in the TP group. There was no significant difference between the two groups (P> 0.05). The 1-year recurrence-free survival rate and 1-year distant metastasis-free survival rate were 92% in the TN group and 96% in the TP group, respectively; 88% and 92% in the PF group, respectively ). The myelotoxicity in TN group was higher than that in TP group (P <0.05). The TP in group TP was higher than that in TN group (P <0.05). Liver and kidney toxicity, no significant difference between the two groups (P <0.05). Conclusion: Nedaplatin combined with paclitaxel concurrent radiotherapy for the treatment of locally advanced cervical esophageal cancer has definite curative effect, low toxicity and good tolerance.